Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
Year-over-year operating income growth rate
Latest
47.70%
↑ 460% vs avg
Percentile
P100
Near historical high
Streak
1 qtr
Consecutive growthAccelerating
Average
-13.25%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 47.70% |
| Q3 2025 | -141.46% |
| Q2 2025 | 40.48% |
| Q1 2025 | -18.38% |
| Q4 2024 | 42.40% |
| Q3 2024 | 28.44% |
| Q2 2024 | -6.91% |
| Q1 2024 | -29.75% |
| Q4 2023 | -18.92% |
| Q3 2023 | -13.98% |
| Q2 2023 | -10.36% |
| Q1 2023 | 8.16% |
| Q4 2022 | -6.08% |
| Q3 2022 | -14.43% |
| Q2 2022 | -22.03% |
| Q1 2022 | 10.86% |
| Q4 2021 | -2.28% |
| Q3 2021 | -2.30% |
| Q2 2021 | -16.54% |
| Q1 2021 | 11.04% |
| Q4 2020 | -1.31% |
| Q3 2020 | -16.81% |
| Q2 2020 | -32.42% |
| Q1 2020 | -26.88% |
| Q4 2019 | -23.80% |
| Q3 2019 | -6.57% |
| Q2 2019 | -25.30% |
| Q1 2019 | -25.36% |
| Q4 2018 | -27.54% |
| Q3 2018 | -44.81% |
| Q2 2018 | -10.71% |
| Q1 2018 | 20.67% |
| Q4 2017 | -3.17% |
| Q3 2017 | -2.35% |
| Q2 2017 | -38.91% |
| Q1 2017 | 20.93% |
| Q4 2016 | 44.96% |
| Q3 2016 | -300.10% |
| Q2 2016 | 45.88% |
| Q1 2016 | 37.89% |